Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis

Overview of attention for article published in PLOS Medicine, August 2016

Altmetric Badge

About this Attention Score

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 70,068 followers.

Adjuvant Trastuzumab in HER2-Positive Early #Breast #Cancer by Age and Hormone Receptor Status https://t.co/jlt899tMa6

#new Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor… https://t.co/J9xMGjpcvE https://t.co/rl2DT1fm78

Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A… https://t.co/rbjGcYPYLu #breastcancer

Adjuvant Trastuzumab in HER2-Positive Early Breast #Cancer by Age and Hormone Receptor Status https://t.co/qsyjkBY0nf

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.